Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma

Lignende værker

• Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?
  af: de Baere, Thierry, et al.
  Udgivet: (2016)
• Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial – PACHA-01 (NCT02494973)
  af: Diane Goéré, et al.
  Udgivet: (2018-08-01)
• Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial – PACHA-01 (NCT02494973)
  af: Goéré, Diane, et al.
  Udgivet: (2018)
• Bilateral adrenal haematoma complicated by adrenal insufficiency in a patient treated with bevacizumab
  af: Smolenschi, Cristina, et al.
  Udgivet: (2021)
• Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival
  af: Oberic, Lucie, et al.
  Udgivet: (2011)